BRIDGEWATER, N.J.--(BUSINESS WIRE)--Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced top-line data from three separate Phase II trials involving its lead cholesterol management compound, AEGR-733, which is a microsomal triglyceride transfer protein (MTP) inhibitor. All three trials were designed to evaluate the efficacy, safety and tolerability of low doses of AEGR-733 alone and in combination with other lipid lowering agents such as Lipitor, Zetia and fenofibrate. The largest trial also included magnetic resonance spectroscopy (MRS) to quantify patients’ hepatic fat levels. Preliminary data from the trials indicates statistically significant reductions in patients’ low-density-lipoprotein cholesterol (LDL-C) vs. baseline, while at the same time suggesting a promising safety and tolerability profile, including low levels of hepatic fat accumulation.
